demcizumab dɛmˈsɪzʊmæb humanized monoclonal antibody used treat patients pancreatic cancer nonsmall cell lung cancer demcizumab completed phase trials currently undergoing phase trials demcizumab developed oncomed pharmaceuticals collaboration demcizumab blocks deltalike ligand ligand notch receptors notch signaling implicated key signaling pathway cancer stem cells treating patients combination demcizumab cytotoxic chemotherapy hoped durable antitumor response achieved chemotherapy alonecitation needed demcizumab known cause many adverse effects patient common side effects hypertension fatigue anemia headaches adverse effect nausea hypoalbuminemia dizziness dyspnea occurred finally uncommon side effects heart related illness forming half way patients chosen older life expectancy greater three months histologically confirmed melastic normal hematologic clotting parameters patients excluded received therapy four weeks earlier known hiv infection bleeding disorder receiving anticoagulants uncontrolled hypertension pregnant nursing addition people new york heart association functional classification ii iii iv uncontrolled seizers active neurological diseases significant intercurrent illness phase trials shows drug durable antitumor response phase trials shows safety pharmacokinetics help decide maximum tolerated dose dosed fiftyfive patients either weekly doses ranging mgkg dosed biweekly doses ranging mgkg phase trials show demcizumab tolerable short term safety profile common side effects hypertension fatigue recommended dose mgkg research holding phase trials yosemite trial testing demcizumab abraxane gemcitabine verses using abraxane gemcitabine pancreatic cancer second phase trial denali testing demcizumab pemetrexed carboplatin verses pemetrexed carboplatin alone nonsmall cell lung cancer patients patients similar subjects phase trials demcizumabcitation needed yosemite trial double blind randomized arm study subjects metastatic pancreatic cancer primary purpose study assess efficacy safety demcizumab abraxane plus gemcitabine compared standard care phase dose demcizumab mgkg every two weeks april oncomed announced trial failed meet primary endpoint demcizumab significant effect phase trial denali trial nonsmall cell lung cancer randomized arm study subjects firstline metastatic stage iv nonsquamous nonsmallcell lung cancer tumors must epidermal growth factor receptor anaplastic lymphoma kinase primary objective study progressionfree survival secondary objectives response rate duration response overall survival safety immunogenicity pharmacokinetics randomized subject receive carboplatin pemetrexed four cycles followed pemetrexed maintenance denali trial completed end clinical testing since discontinued following results second oncomed pharmaceuticals received phase data favorable outcomes company oncomed believes ability codevelop copromote demcizumab celgene united states give company success demcizumab onocmed given royalty charge codevelopment copromote drug released united states year released european union price demcizumab thousand dollars united states thousand dollars exus pancreatic cancer celgene approximately make million million nonsmall cell lung cancer celgene approximately make billion million httpsenwikipediaorgwikidemcizumab